Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
- Won-Jung Koh; Seung Heon Lee; Young Ae Kang; Chang-Hoon Lee; Jae Chol Choi; Jae Ho Lee; Seung Hun Jang; Kwang Ha Yoo; Ki Hwan Jung; Ki Uk Kim; Sang Bong Choi; Yon Ju Ryu; Kyung Chan Kim; Soojung Um; Yong Soo Kwon; Yee Hyung Kim; Won-Il Choi; Kyeongman Jeon; Yong Il Hwang; Se Joong Kim; Young Seok Lee; Eun Young Heo; Juhee Lee; Yeo WoonKi; Tae Sun Shim; Jae-Joon Yim
- Dept. of Internal Medicine (내과학)
- Issue Date
- American Journal of Respiratory and Critical Care Medicine, Vol.188(7) : 858-64, 2013
- Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking.
Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB.
Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions.
Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27–2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75).
Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment.
Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).
KEYWORDS: multidrug-resistant tuberculosis, fluoroquinolone, moxifloxacin, levofloxacin
Read More: http://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0604OC#.VoxntU8axZQ
- Appears in Collections:
- 1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
- Keimyung Author(s)
- Full Text
- File in this Item
- RIS (EndNote)
- XLS (Excel)